Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.

Capellades J, Puig J, Domenech S, Pujol T, Oleaga L, Camins A, Majós C, Diaz R, de Quintana C, Teixidor P, Conesa G, Plans G, Gonzalez J, García-Balañà N, Velarde JM, Balaña C.

J Neurooncol. 2017 Dec 28. doi: 10.1007/s11060-017-2726-z. [Epub ahead of print]

PMID:
29285591
2.

Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.

Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patiño A, Arrieta O, Hakim EJ, Hakim F, Mejía JA, Useche N, Bermúdez S, Carranza H, Vargas C, Otero J, Mayor LC, Ortíz LD, Franco S, Ortíz C, Gil-Gil M, Balaña C, Zatarain-Barrón ZL.

J Neurooncol. 2018 Jan;136(2):363-371. doi: 10.1007/s11060-017-2660-0. Epub 2017 Nov 25.

PMID:
29177594
3.

Pseudoprogression as an adverse event of glioblastoma therapy.

Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group.

Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3.

4.

SEOM clinical guidelines for anaplastic gliomas (2017).

Balañá C, Alonso M, Hernandez A, Perez-Segura P, Pineda E, Ramos A, Sanchez AR, Teixidor P, Verger E, Benavides M.

Clin Transl Oncol. 2018 Jan;20(1):16-21. doi: 10.1007/s12094-017-1762-7. Epub 2017 Oct 20.

5.

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.

J Neurooncol. 2017 Nov;135(2):273-284. doi: 10.1007/s11060-017-2570-1. Epub 2017 Sep 7.

PMID:
28884377
6.

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Aug;18(8):e430-e431. doi: 10.1016/S1470-2045(17)30515-6. Epub 2017 Jul 26. No abstract available.

PMID:
28759377
7.

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.

Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A.

Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105.

PMID:
28575464
8.

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Review. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

PMID:
28483413
9.

A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples.

Esteve-Codina A, Arpi O, Martinez-García M, Pineda E, Mallo M, Gut M, Carrato C, Rovira A, Lopez R, Tortosa A, Dabad M, Del Barco S, Heath S, Bagué S, Ribalta T, Alameda F, de la Iglesia N, Balaña C; GLIOCAT Group.

PLoS One. 2017 Jan 25;12(1):e0170632. doi: 10.1371/journal.pone.0170632. eCollection 2017.

10.

Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines.

Capellades J, Teixidor P, Villalba G, Hostalot C, Plans G, Armengol R, Medrano S, Estival A, Luque R, Gonzalez S, Gil-Gil M, Villa S, Sepulveda J, García-Mosquera JJ, Balana C.

Clin Transl Oncol. 2017 Jun;19(6):727-734. doi: 10.1007/s12094-016-1598-6. Epub 2016 Dec 22.

PMID:
28005261
11.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS.

J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5.

PMID:
27918718
12.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

13.

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.

Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. Epub 2016 Aug 27.

PMID:
27575023
14.

Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.

Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, Reynes G, Herrero A, De Las Peñas R, Luque R, Capellades J, Balaña C, Pérez-García VM.

PLoS One. 2016 Aug 24;11(8):e0161484. doi: 10.1371/journal.pone.0161484. eCollection 2016.

15.

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A.

J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16.

PMID:
27185843
16.

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.

Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S.

J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3.

PMID:
26847813
17.

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.

Reynés G, Martínez-Sales V, Vila V, Balañá C, Pérez-Segura P, Vaz MA, Benavides M, Gallego O, Palomero I, Gil-Gil M, Fleitas T, Reche E.

Anticancer Drugs. 2016 Feb;27(2):133-7. doi: 10.1097/CAD.0000000000000314.

PMID:
26574999
18.

Economic Analysis Of Epicup, An Epigenetic Test To Predict The Tissue Of Origin In Cancer Of Unknown Primary Site, The Usa Payors Perspective.

Gracia A, Balañá C, Kaskens L, Chiavenna S, Matias-Guiu X, Rubio-Rodríguez D, Rubio-Terrés C, Iglesias L, Esteller M.

Value Health. 2015 Nov;18(7):A356. doi: 10.1016/j.jval.2015.09.670. Epub 2015 Oct 20. No abstract available.

19.

Economic Analysis Of Epicup, An Epigenetic Test To Predict The Tissue Of Origin In Cancer Of Unknown Primary Site, From The Spanish Nhs Perspective.

Gracia A, Balañá C, Kaskens L, Chiavenna S, Matias-Guiu X, Rubio-Rodríguez D, Rubio-Terrés C, Iglesias L, Esteller M.

Value Health. 2015 Nov;18(7):A356-7. doi: 10.1016/j.jval.2015.09.672. Epub 2015 Oct 20. No abstract available.

20.

A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.

Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, Pérez-Segura P, Berrocal A, Reynés G, Gallego O, Capellades J, Ordoñez JM, La Orden B, Balañá C.

Clin Transl Oncol. 2015 Sep;17(9):743-50. doi: 10.1007/s12094-015-1304-0. Epub 2015 Jun 2.

PMID:
26033428
21.

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma.

Lancet Oncol. 2014 Aug;15(9):e395-403. doi: 10.1016/S1470-2045(14)70011-7. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.

22.

Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.

Balaña C, Gil MJ, Perez P, Reynes G, Gallego O, Ribalta T, Capellades J, Gonzalez S, Verger E.

Target Oncol. 2014 Dec;9(4):321-9. doi: 10.1007/s11523-014-0305-1. Epub 2014 Jan 15.

PMID:
24424564
23.

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.

Capdevila L, Cros S, Ramirez JL, Sanz C, Carrato C, Romeo M, Etxaniz O, Hostalot C, Massuet A, Cuadra JL, Villà S, Balañà C.

J Neurooncol. 2014 Mar;117(1):77-84. doi: 10.1007/s11060-013-1352-7. Epub 2014 Jan 7.

PMID:
24395350
24.

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.

Gallego O, Cuatrecasas M, Benavides M, Segura PP, Berrocal A, Erill N, Colomer A, Quintana MJ, Balaña C, Gil M, Gallardo A, Murata P, Barnadas A.

J Neurooncol. 2014 Jan;116(2):413-9. doi: 10.1007/s11060-013-1316-y. Epub 2013 Dec 19. Erratum in: J Neurooncol. 2014 Dec;120(3):667.

25.

Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.

Villà S, Balañà C, Comas S.

Chin J Cancer. 2014 Jan;33(1):25-31. doi: 10.5732/cjc.013.10216. Epub 2013 Dec 11. Review.

26.

A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.

Reynés G, Balañá C, Gallego O, Iglesias L, Pérez P, García JL.

Anticancer Drugs. 2014 Jul;25(6):717-22. doi: 10.1097/CAD.0000000000000059.

PMID:
24322542
27.

Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.

Balañá C, Vaz MA, Lopez D, de la Peñas R, García-Bueno JM, Molina-Garrido MJ, Sepúlveda JM, Cano JM, Bugés C, Sanz SM, Arranz JL, Perez-Segura P, Rodriguez A, Martin JM, Benavides M, Gil M.

Clin Transl Oncol. 2014 Mar;16(3):273-9. doi: 10.1007/s12094-013-1068-3. Epub 2013 Jun 21.

PMID:
23793813
28.

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.

Sardinha R, Hernández T, Fraile S, Tresserra F, Vidal A, Gómez MC, Astudillo A, Hernández N, Saenz de Santamaría J, Ordi J, Gonçalves L, Ramos R, Balañá C, de Álava E.

Clin Sarcoma Res. 2013 Mar 7;3(1):3. doi: 10.1186/2045-3329-3-3.

29.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD.

Eur J Cancer. 2012 Nov;48(16):3036-44. doi: 10.1016/j.ejca.2012.05.012. Epub 2012 Jun 29.

PMID:
22749255
30.

SEOM guideline for the treatment of malignant glioma.

Berrocal A, Gil M, Gallego Ó, Balaña C, Pérez Segura P, García-Mata J, Reynes G; SEOM (Spanish Society of Clinical Oncology).

Clin Transl Oncol. 2012 Jul;14(7):545-50.

PMID:
22721801
31.

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O, Fernández-Chacón C, Martínez-García M, Herrero A, Andrés R, Benavides M, Quintanar T, Pérez-Martin X.

Anticancer Drugs. 2012 Jul;23(6):659-65. doi: 10.1097/CAD.0b013e3283534d3e.

PMID:
22634799
32.

Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.

Segura PP, Gil M, Balañá C, Chacón I, Langa JM, Martín M, Bruna J.

J Neurooncol. 2012 Aug;109(1):137-42. doi: 10.1007/s11060-012-0879-3. Epub 2012 May 20.

PMID:
22610937
33.

Evolution of care for patients with relapsed glioblastoma.

Balañá C, Villá S, Teixidor P.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1719-29. doi: 10.1586/era.11.152. Review.

PMID:
22050021
34.

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.

Balańa C, Carrato C, Ramírez JL, Cardona AF, Berdiel M, Sánchez JJ, Tarón M, Hostalot C, Musulen E, Ariza A, Rosell R.

Clin Transl Oncol. 2011 Sep;13(9):677-85. doi: 10.1007/s12094-011-0714-x.

PMID:
21865140
35.

Update on the diagnosis of cancer of unknown primary (CUP) origin.

Ariza A, Balañá C, Concha Á, Hitt R, Homet B, Matilla A, Alba E.

Clin Transl Oncol. 2011 Jul;13(7):434-41. doi: 10.1007/s12094-011-0679-9.

PMID:
21775269
36.

Stem cells in brain tumorigenesis and their impact on therapy.

Cardona AF, Balañá C, Torres D, Becerra H, Ortíz LD, Fadul CE.

Curr Stem Cell Res Ther. 2011 Dec;6(4):339-49. Review.

PMID:
21466481
37.

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Balañá C, Etxaniz O, Bugés C, Martínez A.

Clin Transl Oncol. 2011 Mar;13(3):209-10. doi: 10.1007/s12094-011-0642-9. No abstract available.

PMID:
21421467
38.

Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study.

Villà S, Weber DC, Moretones C, Mañes A, Combescure C, Jové J, Puyalto P, Cuadras P, Bruna J, Verger E, Balañà C, Graus F.

Radiat Oncol. 2011 Mar 2;6:23. doi: 10.1186/1748-717X-6-23.

39.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanović A, Cortes-Funes H, Buesa JM.

Invest New Drugs. 2012 Apr;30(2):729-40. doi: 10.1007/s10637-010-9561-9. Epub 2010 Oct 20.

PMID:
20960029
40.

Extended-schedule dose-dense temozolomide in refractory gliomas.

Berrocal A, Perez Segura P, Gil M, Balaña C, Garcia Lopez J, Yaya R, Rodríguez J, Reynes G, Gallego O, Iglesias L; GENOM Cooperative Group.

J Neurooncol. 2010 Feb;96(3):417-22. doi: 10.1007/s11060-009-9980-7. Epub 2009 Aug 8.

41.

Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.

Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM.

J Clin Oncol. 2009 Apr 10;27(11):1893-8. doi: 10.1200/JCO.2008.19.2930. Epub 2009 Mar 9.

PMID:
19273704
42.

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS).

Poveda A, López-Pousa A, Martín J, Del Muro JG, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM.

Sarcoma. 2005;9(3-4):127-32. doi: 10.1080/13577140500287024.

43.

Translational research in glioblastoma multiforme: molecular criteria for patient selection.

Rosell R, de Las Peñas R, Balaña C, Santarpia M, Salazar F, de Aguirre I, Reguart N, Villa S, Wei J, Ramirez JL, Molina MA, Ramon y Cajal S, Jablons D, Taron M.

Future Oncol. 2008 Apr;4(2):219-28. doi: 10.2217/14796694.4.2.219. Review.

PMID:
18407735
44.

Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment.

Balaña C, Capellades J, Teixidor P, Roussos I, Ballester R, Cuello M, Arellano A, Florensa R, Rosell R.

Clin Transl Oncol. 2007 Dec;9(12):797-803.

PMID:
18158984
45.

Medulloblastoma in young adults. Must we give adjuvant chemotherapy?

Roussos I, Balaña C, Cuadras P, Ballester R, Etxaniz O, Hostalot C.

Clin Transl Oncol. 2007 Feb;9(2):121-3.

PMID:
17329226
46.

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.

López-Pousa A, Losa R, Martín J, Maurel J, Fra J, Sierra M, Casado A, García Del Muro J, Poveda A, Balañá C, Martínez-Trufero J, Esteban E, Buesa JM.

Br J Cancer. 2006 Jun 19;94(12):1797-802. Epub 2006 May 23.

47.

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.

Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balaña C.

Gynecol Oncol. 2006 Jun;101(3):545-7. Epub 2006 Feb 20.

PMID:
16487996
48.

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

González-Martín AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balañá C, Martínez E, Herrero A, Pardo B, Adrover E, Rifá J, Godes MJ, Moyano A, Cervantes A.

Ann Oncol. 2005 May;16(5):749-55. Epub 2005 Apr 7.

PMID:
15817604
49.

Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).

Balaña C, López-Pousa A, Berrocal A, Yaya-Tur R, Herrero A, García JL, Martín-Broto J, Benavides M, Cerdá-Nicolás M, Ballester R, Balart J, Capellades J.

J Neurooncol. 2004 Dec;70(3):359-69.

PMID:
15662978
50.

The biology of non-small-cell lung cancer: identifying new targets for rational therapy.

Rosell R, Felip E, Garcia-Campelo R, Balaña C.

Lung Cancer. 2004 Nov;46(2):135-48. Review.

PMID:
15474661

Supplemental Content

Loading ...
Support Center